---
title: 'Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3
  trial results'
date: '2023-08-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37582952/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230816180920&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific
  antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory
  multiple myeloma received subcutaneous elranatamab once weekly after two step-up
  priming doses. After six cycles, persistent responders switched to biweekly dosing.
  Results from cohort A, which enrolled patients without prior BCMA-directed therapy
  (n = 123) are reported. The primary endpoint of confirmed objective response rate
  ...
disable_comments: true
---
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (n = 123) are reported. The primary endpoint of confirmed objective response rate ...